SCHEMBL799164

SCHEMBL799164

C=CCO[C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]2C(C)[C@@]23OC(=O)N(CCCCn2cnc(-c4cccnc4)c2)[C@@H]3[C@@H](C)C(=O)[C@H](C)C[C@]1(C)OC

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.58
ABCC4 O15439 1/20 0.58
ABCB11 O95342 1/20 0.58
CYP3A5 P20815 1/20 0.58
PTGS1 P23219 1/20 0.58
CYP3A7 P24462 1/20 0.58
KCNH2 Q12809 1/20 0.58
CYP3A43 Q9HB55 1/20 0.58
SLCO1B3 Q9NPD5 1/20 0.58
SLCO1B1 Q9Y6L6 1/20 0.58
CYP2E1 P05181 1/20 0.32
CYP2A6 P11509 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2B6 P20813 1/20 0.32
CYP2C19 P33261 1/20 0.32
HDAC1 Q13547 2/20 0.31
HDAC8 Q9BY41 2/20 0.31
HDAC6 Q9UBN7 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL784963 0.89 CYP3A4 (0.72) CYP3A4ABCC4ABCB11CYP3A5PTGS1
SCHEMBL13655585 0.89 CYP3A4 (0.61) CYP3A4ABCC4ABCB11CYP3A5PTGS1
SCHEMBL799508 0.89 CYP3A4 (0.61) CYP3A4ABCC4ABCB11CYP3A5PTGS1
SCHEMBL13655659 0.85 CYP3A4 (0.59) CYP3A4ABCC4ABCB11CYP3A5PTGS1
SCHEMBL13655584 0.81 CYP3A4 (0.53) CYP3A4ABCC4ABCB11CYP3A5PTGS1
SCHEMBL10270380 0.81 CYP3A4 (0.65) CYP3A4ABCC4ABCB11CYP3A5PTGS1
SCHEMBL9968998 0.80 CYP3A4 (0.73) CYP3A4ABCC4ABCB11CYP3A5PTGS1
SCHEMBL784787 0.78 CYP3A4 (0.76) CYP3A4ABCC4ABCB11CYP3A5PTGS1
SCHEMBL15998080 0.78 CYP3A4 (0.76) CYP3A4ABCC4ABCB11CYP3A5PTGS1
SCHEMBL14625955 0.77 CYP3A4 (0.73) CYP3A4ABCC4ABCB11CYP3A5PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343936-B2 Antibacterial agents OPTIMER PHARMACEUTICALS, INC. (US) 2013-01-01 US disclosed
US-20120071429-A1 Novel antibacterial agents TETARD, INC. 2012-03-22 US disclosed
US-8012943-B2 Antibacterial agents OPTIMER PHARMACEUTICALS, INC. (US) 2011-09-06 US disclosed
US-7601695-B2 11-N-[4-(4-Pyridin-3-yl-imidazol-1-yl)-butyl]-6-O-methyl-5-O-(3-dimethylamino-2-hydroxy-propoxy)-3-oxo-erythronolide A, 11,12-carbamate; functionalized macrolides; antiviral, antiprotozoal, anticancer and antigastrointestinal OPTIMER PHARMACEUTICALS, INC. (US) 2009-10-13 US disclosed
US-20090209593-A1 NOVEL ANTIBACTERIAL AGENTS TETARD, INC. 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071429-A1 Novel antibacterial agents MRPL21, CTSA, MRPL12 CYP3A4 4197/4885ABCC4 821/4885ABCB11 578/4885
US-20090209593-A1 NOVEL ANTIBACTERIAL AGENTS MRPL21, MRPL12, CTSA CYP3A4 4368/4885ABCC4 1135/4885ABCB11 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.